HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

NCT06383078 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Efficacy and Safety

Interventions

DRUG: HR070803
DRUG: Oxaliplatin
DRUG: Tegafur
DRUG: Folinic acid
DRUG: 5-Fluorouracil

Sponsor

The First Affiliated Hospital with Nanjing Medical University